{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T04:43:36Z","timestamp":1791089016075,"version":"4.1.0"},"reference-count":33,"publisher":"Public Library of Science (PLoS)","issue":"6","license":[{"start":{"date-parts":[[2012,6,27]],"date-time":"2012-06-27T00:00:00Z","timestamp":1340755200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0036979","type":"journal-article","created":{"date-parts":[[2012,6,27]],"date-time":"2012-06-27T22:08:42Z","timestamp":1340834922000},"page":"e36979","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":58,"title":["Phase II Trial of Concurrent Sunitinib and Image-Guided Radiotherapy for Oligometastases"],"prefix":"10.1371","volume":"7","clinical-trial-number":[{"clinical-trial-number":"nct00463060","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Charles C. L.","family":"Tong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric C.","family":"Ko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Max W.","family":"Sung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jamie A.","family":"Cesaretti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard G.","family":"Stock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stuart H.","family":"Packer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"Forsythe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric M.","family":"Genden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Myron","family":"Schwartz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K. H. Vincent","family":"Lau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Galsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junko","family":"Ozao-Choy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shu-hsia","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johnny","family":"Kao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2012,6,27]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1200\/JCO.1995.13.1.8","article-title":"Oligometastases.","volume":"13","author":"S Hellman","year":"1995","journal-title":"J Clin Oncol"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1002\/jso.21102","article-title":"A rationale for the targeted treatment of oligometastases with radiotherapy.","volume":"98","author":"DM Macdermed","year":"2008","journal-title":"J Surg Oncol"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1200\/JCO.2008.20.0600","article-title":"Phase I study of individualized stereotactic body radiotherapy of liver metastases.","volume":"27","author":"MT Lee","year":"2009","journal-title":"J Clin Oncol"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1002\/cncr.23209","article-title":"A prospective pilot study of curative-intent stereotactic body radiation therapy in patients with 5 or fewer oligometastatic lesions.","volume":"112","author":"MT Milano","year":"2008","journal-title":"Cancer"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1200\/JCO.2008.19.6386","article-title":"Multi-institutional phase I\/II trial of stereotactic body radiation therapy for lung metastases.","volume":"27","author":"KE Rusthoven","year":"2009","journal-title":"J Clin Oncol"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1200\/JCO.2008.19.6329","article-title":"Multi-institutional phase I\/II trial of stereotactic body radiation therapy for liver metastases.","volume":"27","author":"KE Rusthoven","year":"2009","journal-title":"J Clin Oncol"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"5255","DOI":"10.1158\/1078-0432.CCR-08-0358","article-title":"An initial report of a radiation dose-escalation trial in patients with one to five sites of metastatic disease.","volume":"14","author":"JK Salama","year":"2008","journal-title":"Clin Cancer Res"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/1748-717X-3-36","article-title":"Normal tissue toxicity after small field hypofractionated stereotactic body radiation.","volume":"3","author":"MT Milano","year":"2008","journal-title":"Radiat Oncol"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/S0360-3016(00)00697-0","article-title":"Postoperative radiotherapy for lung cancer: the breast cancer story all over again?","volume":"48","author":"LB Marks","year":"2000","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1038\/ncponc0714","article-title":"The concurrent chemoradiation paradigm\u2013general principles.","volume":"4","author":"TY Seiwert","year":"2007","journal-title":"Nat Clin Pract Oncol"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1200\/JCO.2006.06.3602","article-title":"Sunitinib: from rational design to clinical efficacy.","volume":"25","author":"LQ Chow","year":"2007","journal-title":"J Clin Oncol"},{"key":"ref12","first-page":"4009","article-title":"SU11248 maintenance therapy prevents tumor regrowth after fractionated irradiation of murine tumor models.","volume":"63","author":"AJ Schueneman","year":"2003","journal-title":"Cancer Res"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"2514","DOI":"10.1158\/0008-5472.CAN-08-4709","article-title":"The novel role of tyrosine kinase inhibitor in the reversal of immune suppression and modulation of tumor microenvironment for immune-based cancer therapies.","volume":"69","author":"J Ozao-Choy","year":"2009","journal-title":"Cancer Res"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"3571","DOI":"10.1002\/cncr.24412","article-title":"Phase 1 study of concurrent sunitinib and image-guided radiotherapy followed by maintenance sunitinib for patients with oligometastases: acute toxicity and preliminary response.","volume":"115","author":"J Kao","year":"2009","journal-title":"Cancer"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"122S","DOI":"10.2967\/jnumed.108.057307","article-title":"From RECIST to PERCIST: Evolving Considerations for PET response criteria in solid tumors.","volume":"50","author":"RL Wahl","year":"2009","journal-title":"J Nucl Med"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1016\/S1470-2045(09)70222-0","article-title":"Risk of bleeding with vascular endothelial growth factor receptor tyrosine-kinase inhibitors sunitinib and sorafenib: a systematic review and meta-analysis of clinical trials.","volume":"10","author":"Y Je","year":"2009","journal-title":"Lancet Oncol"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1056\/NEJMoa033025","article-title":"Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer.","volume":"351","author":"D Cunningham","year":"2004","journal-title":"N Engl J Med"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"2733","DOI":"10.1056\/NEJMoa064320","article-title":"Lapatinib plus capecitabine for HER2-positive advanced breast cancer.","volume":"355","author":"CE Geyer","year":"2006","journal-title":"N Engl J Med"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1056\/NEJMoa032691","article-title":"Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.","volume":"350","author":"H Hurwitz","year":"2004","journal-title":"N Engl J Med"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1056\/NEJMoa071834","article-title":"Cetuximab for the treatment of colorectal cancer.","volume":"357","author":"DJ Jonker","year":"2007","journal-title":"N Engl J Med"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"2666","DOI":"10.1056\/NEJMoa072113","article-title":"Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer.","volume":"357","author":"K Miller","year":"2007","journal-title":"N Engl J Med"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1056\/NEJMoa041318","article-title":"Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer.","volume":"351","author":"DP Petrylak","year":"2004","journal-title":"N Engl J Med"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"2542","DOI":"10.1056\/NEJMoa061884","article-title":"Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer.","volume":"355","author":"A Sandler","year":"2006","journal-title":"N Engl J Med"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1056\/NEJMoa050753","article-title":"Erlotinib in previously treated non-small-cell lung cancer.","volume":"353","author":"FA Shepherd","year":"2005","journal-title":"N Engl J Med"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1056\/NEJM200103153441101","article-title":"Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.","volume":"344","author":"DJ Slamon","year":"2001","journal-title":"N Engl J Med"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1056\/NEJMoa040720","article-title":"Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.","volume":"351","author":"IF Tannock","year":"2004","journal-title":"N Engl J Med"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1056\/NEJMoa065044","article-title":"Sunitinib versus interferon alfa in metastatic renal-cell carcinoma.","volume":"356","author":"RJ Motzer","year":"2007","journal-title":"N Engl J Med"},{"key":"ref28","first-page":"1677","article-title":"Analysis of further disease progression in metastatic non-small cell lung cancer: implications for locoregional treatment.","volume":"25","author":"N Mehta","year":"2004","journal-title":"Int J Oncol"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1038\/28412","article-title":"Combined effects of angiostatin and ionizing radiation in antitumour therapy.","volume":"394","author":"HJ Mauceri","year":"1998","journal-title":"Nature"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"2148","DOI":"10.1158\/1078-0432.CCR-08-1332","article-title":"Sunitinib mediates reversal of myeloid-derived suppressor cell accumulation in renal cell carcinoma patients.","volume":"15","author":"JS Ko","year":"2009","journal-title":"Clin Cancer Res"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.canlet.2009.06.026","article-title":"HPV-induced oropharyngeal cancer, immune response and response to therapy.","volume":"288","author":"HL Vu","year":"2010","journal-title":"Cancer Lett"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1182\/blood-2009-02-206870","article-title":"Therapeutic effects of ablative radiation on local tumor require CD8+ T cells: changing strategies for cancer treatment.","volume":"114","author":"Y Lee","year":"2009","journal-title":"Blood"},{"key":"ref33","article-title":"Targeting immune suppressing myeloid-derived suppressor cells in oncology.","author":"J Kao","year":"2010"}],"container-title":["PLoS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0036979","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,10,24]],"date-time":"2018-10-24T07:03:41Z","timestamp":1540364621000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0036979"}},"subtitle":[],"editor":[{"given":"Maciej S.","family":"Lesniak","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2012,6,27]]},"references-count":33,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2012,6,27]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0036979","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,6,27]]}}}